Anti-N3pGlu amyloid beta peptide antibodies and uses thereof
The present invention provides anti-N3pGlu Aβ antibodies or antigen-binding fragment thereof. In addition, the present invention provides the use of the anti-N3pGlu Aβ antibodies or antigen-binding fragment thereof for the treatment of Alzheimer's disease.
1. A human engineered anti-N3pGlu Aβ antibody comprising a Light chain Variable Region (LCVR) and a Heavy chain Variable Region (HCVR) wherein LCDR1 is KSX1X2SLLYSRX3KTYLN (SEQ ID NO: 51), LCDR2 is AVSKLX4S (SEQ ID NO: 52), LCDR3 is VQGTHYPFT (SEQ ID NO: 5) and HCDR1 is GYX5FTX6YYIN (SEQ ID NO: 53), HCDR2 is WINPGSGNTKYNEKFKG (SEQ ID NO: 8), and HCDR3 is EGX7TVY (SEQ ID NO: 54), wherein X1 is S or T; X2 is Q or R, X3 is G or S, X4 is D or G, X5 is D or T, X6 is R or D, and X7 is I, T, E, or V.
2. The human engineered anti-N3pGlu Aβ antibody of claim 1 , wherein the LCVR framework is substantially human VK02 light chain germ line sequence and the HCVR framework is substantially human VH5-51 heavy chain germ line sequence.
3. A pharmaceutical composition comprising the human engineered antibody of claim 1 , and a pharmaceutically acceptable carrier, diluent, or excipient.
4. A pharmaceutical composition comprising the human engineered antibody of claim 2 , and a pharmaceutically acceptable carrier, diluent, or excipient.
5. A method of treating a condition selected from the group consisting of clinical or pre-clinical Alzheimer's disease, prodromal Alzheimer's disease, Down's syndrome, and clinical or pre-clinical cerebral amyloid angiopathy (CAA), comprising administering to a human in need thereof the human engineered antibody of claim 1 .
6. A method of treating a condition selected from the group consisting of clinical or pre-clinical Alzheimer's disease, prodromal Alzheimer's disease, Down's syndrome, and clinical or pre-clinical cerebral amyloid angiopathy (CAA), comprising administering to a human in need thereof the human engineered antibody of claim 2 .
7. A method of treating a condition selected from the group consisting of clinical or pre-clinical Alzheimer's disease, prodromal Alzheimer's disease, Down's syndrome, and clinical or pre-clinical cerebral amyloid angiopathy (CAA), comprising administering to a human in need thereof the pharmaceutical composition of claim 3 .
8. A method of treating a condition selected from the group consisting of clinical or pre-clinical Alzheimer's disease, prodromal Alzheimer's disease, Down's syndrome, and clinical or pre-clinical cerebral amyloid angiopathy (CAA), comprising administering to a human in need thereof the pharmaceutical composition of claim 4 .
9. A method of treating Alzheimer's disease, comprising administering to a human in need thereof the human engineered antibody of claim 1 .
10. A method of treating Alzheimer's disease, comprising administering to a human in need thereof the human engineered antibody of claim 1 .
11. A method of treating Alzheimer's disease, comprising administering to a human in need thereof the pharmaceutical composition of claim 3 .
12. A method of treating Alzheimer's disease, comprising administering to a human in need thereof the pharmaceutical composition of claim 4 .